Holen Sie sich die Stockscreener-App
5.69
3.89%
-0.23
Handel nachbörslich:
5.97
0.28
+4.92%
Schlusskurs vom Vortag:
$5.92
Offen:
$5.92
24-Stunden-Volumen:
84,289
Relative Volume:
0.41
Marktkapitalisierung:
$243.24M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-3.9142
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
-1.90%
1M Leistung:
-0.70%
6M Leistung:
-20.86%
1J Leistung:
-68.49%
1-Tages-Spanne:
$5.61
$6.045
1-Wochen-Bereich:
$5.33
$6.045
52-Wochen-Spanne:
$1.97
$22.46
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
72 HAMMERSMITH ROAD, LONDON
Vergleichen Sie SLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
5.69 | 243.24M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com India
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics (SLN) - Zacks Investment Research
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):